13F Holdings
中文EN

ACET Adicet Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1720580 · Fiscal year ends 12/26

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY20.9%
TTM EPS YoY78.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-85.9%
ROA-67.5%
ROIC (approx.)-97.0%
Asset turnover—

Leverage & solvency

Liabilities / assets20.4%
Debt / equity0.00x
Current ratio6.09x
Interest coverage-1,038.62x

Cash quality & payout

Operating cash flow / net income0.88x
Accruals ratio-8.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$99.13M$99.32M$106.04M$71.25M$48.94M
SG&A expense$22.99M$28.29M$26.53M$26.30M$22.22M
Operating income-$122.11M-$127.61M-$152.04M-$72.55M-$61.43M
Interest expense$36,000$4,000$25,000$80,000$176,000
Pretax income-$116.80M-$117.12M-$142.66M-$69.79M-$62.12M
Income tax$0$0$0$0-$125,000
Net income-$116.80M-$117.12M-$142.66M-$69.79M-$62.00M
EBITDA-$115.73M-$121.15M-$145.94M-$69.98M-$59.90M
EPS (basic)-16.95-21.33-3.31-1.70-2.00
EPS (diluted)-16.95-21.33-3.31-1.70-2.00
Weighted avg. shares (diluted)6.89M5.49M43.04M41.08M30.95M
Balance sheet
Cash & equivalents$38.92M$59.40M$159.71M$257.66M$277.69M
Short-term investments——$0—$0
Current assets$160.93M$180.14M$162.27M$261.04M$282.44M
PP&E, net$16.53M$22.52M$26.78M$28.71M$14.64M
Goodwill——$0$19.46M$19.46M
Intangibles————$0
Total assets$192.35M$220.22M$207.29M$330.69M$338.94M
Current liabilities$21.53M$19.39M$19.29M$19.71M$16.32M
Total liabilities$33.15M$33.61M$37.12M$38.35M$35.81M
Shareholders' equity$159.21M$186.61M$170.18M$292.34M$303.13M
Shares outstanding9.59M5.16M43.27M42.95M39.74M
Cash flow statement
Operating cash flow-$95.25M-$92.38M-$93.72M-$44.77M-$51.05M
Capital expenditure$1.74M$1.12M$4.46M$16.78M$13.05M
Free cash flow-$96.98M-$93.50M-$98.18M-$61.55M-$64.10M
Investing cash flow$2.39M-$119.24M-$4.46M-$16.78M-$2.80M
Financing cash flow$75.25M$111.31M$236,000$41.51M$242.69M
Depreciation & amortization$6.38M$6.47M$6.10M$2.58M$1.54M
Stock-based compensation$14.27M$22.23M$20.26M$17.13M$12.51M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.